Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 06, 2018 08:00 ET | Source: Fibrocell Science Inc

Fibrocell Announces FDA Allowance of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma

EXTON, Pa., March 06, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
February 06, 2018 08:00 ET | Source: Fibrocell Science Inc

Fibrocell to Present at 20th Annual BIO CEO & Investor Conference

EXTON, Pa., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
February 05, 2018 08:00 ET | Source: Fibrocell Science Inc

Fibrocell Announces Submission of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma

EXTON, Pa., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
January 30, 2018 08:00 ET | Source: Fibrocell Science Inc

Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

EXTON, Pa., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
January 24, 2018 08:00 ET | Source: Fibrocell Science Inc

Fibrocell to Present at Phacilitate Cell and Gene Therapy World 2018

EXTON, Pa., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
December 11, 2017 16:01 ET | Source: Fibrocell Science Inc

Fibrocell Announces Closing of $10.5 Million Underwritten Public Offering

EXTON, Pa., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
December 07, 2017 07:00 ET | Source: Fibrocell Science Inc

Fibrocell Announces Pricing of $10.5 Million Underwritten Public Offering

EXTON, Pa., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
November 13, 2017 08:00 ET | Source: Fibrocell Science Inc

Fibrocell Reports Third Quarter 2017 Financial Results and Recent Highlights

EXTON, Pa., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
November 06, 2017 08:00 ET | Source: Fibrocell Science Inc

Fibrocell to Host Conference Call and Webcast on Monday, November 13, 2017 to Discuss Third Quarter 2017 Financial Results and Recent Operational Highlights

EXTON, Pa., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
October 02, 2017 16:30 ET | Source: Fibrocell Science, Inc.

Fibrocell to Present at 2017 Cell & Gene Meeting on the Mesa

EXTON, Pa., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC) today announced that John Maslowski, President and Chief Executive Officer of Fibrocell, will present at 3:00 pm...